NASDAQ:RGNXRegenxbio Stock Price, Forecast & News

Regenxbio's stock was trading at $32.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RGNX stock has increased by 14.1% and is now trading at $37.53. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Regenxbio.

Regenxbio is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Regenxbio.

Regenxbio Inc (NASDAQ:RGNX) released its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.87) by $0.21. The biotechnology company earned $17.60 million during the quarter, compared to analyst estimates of $17.99 million. Regenxbio had a negative return on equity of 27.84% and a negative net margin of 197.23%. The firm's quarterly revenue was up 1855.6% on a year-over-year basis. During the same quarter last year, the business posted ($0.89) earnings per share. View Regenxbio's earnings history.

6 brokers have issued 12 month target prices for Regenxbio's shares. Their forecasts range from $37.00 to $150.00. On average, they expect Regenxbio's share price to reach $70.00 in the next twelve months. This suggests a possible upside of 86.5% from the stock's current price. View analysts' price targets for Regenxbio.

Media coverage about RGNX stock has been trending very negative on Tuesday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Regenxbio earned a media sentiment score of -3.5 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutRegenxbio.

Regenxbio saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 4,000,000 shares, a decrease of 8.0% from the April 30th total of 4,350,000 shares. Based on an average daily trading volume, of 520,200 shares, the short-interest ratio is presently 7.7 days. Currently, 11.5% of the company's shares are short sold. View Regenxbio's Current Options Chain.

Some companies that are related to Regenxbio include Acceleron Pharma (XLRN), Adaptive Biotechnologies (ADPT), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Crispr Therapeutics (CRSP), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), Momenta Pharmaceuticals (MNTA), bluebird bio (BLUE), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Novavax (NVAX), Alector (ALEC), Fate Therapeutics (FATE) and Bill.com (RVMD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regenxbio investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Voyager Therapeutics (VYGR), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Amarin (AMRN), QUALCOMM (QCOM), Bristol-Myers Squibb (BMY) and Square (SQ).

Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."

Regenxbio's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.56%), Redmile Group LLC (6.28%), State Street Corp (5.28%), JPMorgan Chase & Co. (4.04%), WS Management Lllp (1.71%) and UBS Group AG (1.68%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View institutional ownership trends for Regenxbio.

RGNX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Redmile Group LLC, Carmignac Gestion, Perceptive Advisors LLC, WS Management Lllp, Morgan Stanley, Morgan Stanley, and WINTON GROUP Ltd. Company insiders that have sold Regenxbio company stock in the last year include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Patrick J Christmas, and Vittal Vasista. View insider buying and selling activity for Regenxbio.

RGNX stock was acquired by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, JPMorgan Chase & Co., Burrage Capital Management LLC, State Street Corp, First Manhattan Co., Assenagon Asset Management S.A., Foresite Capital Management II LLC, and Korea Investment CORP. View insider buying and selling activity for Regenxbio.

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RGNX stock can currently be purchased for approximately $37.53.

Regenxbio has a market capitalization of $1.40 billion and generates $35.23 million in revenue each year. The biotechnology company earns $-94,730,000.00 in net income (profit) each year or ($3.26) on an earnings per share basis. Regenxbio employs 192 workers across the globe.

The official website for Regenxbio is www.regenxbio.com.

Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]